Abstract
Bestatin, (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine, is an effective inhibitor of the aminopeptidase N and other leucine and arginine aminopeptidases , having the selectivity toward the Aminopeptidase N (APN) and the Aminopeptidase B (APB) which are all metalloproteases belonging to the M1 aminopeptidase family. In spite of the poor selectivity and toxicity, so far, Bestatin is still the only marketed inhibitor of APN for cancer treatment. Considering that the inhibitor of APN is a promising agent to control and treat cancer, many efforts have been made to curtail the whole synthesis of the Bestatin and this mini-review will introduce the whole synthesis of Bestatin.
Keywords: Aminopeptidase N, inhibitors, bestatin, asymmetric synthesis, stereoselectivity, hydroxyamide, oxidizer, reducer
Mini-Reviews in Organic Chemistry
Title: The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Volume: 5 Issue: 2
Author(s): Yepeng Luan, Jiajia Mu and Wenfang Xu
Affiliation:
Keywords: Aminopeptidase N, inhibitors, bestatin, asymmetric synthesis, stereoselectivity, hydroxyamide, oxidizer, reducer
Abstract: Bestatin, (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine, is an effective inhibitor of the aminopeptidase N and other leucine and arginine aminopeptidases , having the selectivity toward the Aminopeptidase N (APN) and the Aminopeptidase B (APB) which are all metalloproteases belonging to the M1 aminopeptidase family. In spite of the poor selectivity and toxicity, so far, Bestatin is still the only marketed inhibitor of APN for cancer treatment. Considering that the inhibitor of APN is a promising agent to control and treat cancer, many efforts have been made to curtail the whole synthesis of the Bestatin and this mini-review will introduce the whole synthesis of Bestatin.
Export Options
About this article
Cite this article as:
Luan Yepeng, Mu Jiajia and Xu Wenfang, The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N, Mini-Reviews in Organic Chemistry 2008; 5 (2) . https://dx.doi.org/10.2174/157019308784223604
DOI https://dx.doi.org/10.2174/157019308784223604 |
Print ISSN 1570-193X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6298 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity
Combinatorial Chemistry & High Throughput Screening Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Some Peculiar Effects of NO-Synthase Inhibition on the Structure and Function of Cardiovascular System
Current Pharmaceutical Biotechnology Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy